CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,198 enrolled
Drug / intervention
Trelagliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03555591
NCT03555591N/ACompleted
CompareCT.gov

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Takeda·observational·Posted Jun 13, 2018·Updated Dec 12, 2023

In Brief

An observational study evaluating Trelagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 3,198 participants across 1 site.

Detailed Summary

The purpose of this survey is to evaluate the long-term safety and efficacy of trelagliptin tablets in patients with type 2 diabetes mellitus in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 13, 2018
Enrollment StartMay 1, 2016
Primary CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 8.1 years ago

Interventions

Trelagliptindrug

Trelagliptin tablets